In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells

Riffo-Campos,Ángela L.; Castillo,Josefa; Vallet-Sánchez,Azahara; Ayala,Guillermo; Cervantes,Andrés; López-Rodas,Gerardo; Franco,Luis

doi:10.3892/or.2016.5210

In silico RNA-seq and experimental analyses reveal the differential expression and splicing of EPDR1 and ZNF518B genes in relation to KRAS mutations in colorectal cancer cells

Authors:
- Ángela L. Riffo-Campos
- Josefa Castillo
- Azahara Vallet-Sánchez
- Guillermo Ayala
- Andrés Cervantes
- Gerardo López-Rodas
- Luis Franco
View Affiliations

Affiliations: Department of Biochemistry and Molecular Biology, University of Valencia, Valencia, Spain, INCLIVA Institute of Health Research, Valencia, Spain, Department of Statistics and Operational Research, University of Valencia, Burjassot, Valencia, Spain
Published online on: October 27, 2016 https://doi.org/10.3892/or.2016.5210
Pages: 3627-3634

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Several drugs used for the treatment of colorectal cancer (CRC) are targeted at the epidermal growth factor receptor, but mutations in genes of the RAS family cause resistance to these drugs. Thus, extensive research is being carried out to counterbalance this resistance. The G13D mutation of KRAS is common in humans, and we previously reported that this mutation results in the epigenetic modification of hnRNP proteins, involved in RNA splicing. As aberrant splicing often results in oncogenicity, the present study aimed to identify the genes which show altered splicing patterns in connection with the G13D KRAS mutation. To accomplish this, we first carried out an in silico analysis of RNA-seq databases and found that the distribution of alternative splicing isoforms of genes RPL13, HSP90B1, ENO1, EPDR1 and ZNF518B was altered in human CRC cell lines carrying the G13D KRAS mutation when compared to cell lines carrying wild-type KRAS. The in silico results were experimentally validated by quantitative real‑time PCR. Expression of the genes EPDR1 and ZNF518B was negligible in the Caco2, RKO and SW48 cell lines, which possess wild-type KRAS, while the HCT116, DLD1 and D-Mut1 cell lines, harbouring the G13D mutation, expressed these genes. Moreover, in both genes, the ratio of isoforms was significantly different between the parental DLD1 (+/G13D) and D-Mut1 cells, in which the wild-type allele had been knocked out. DWT7m cells also expressed both genes. These cells, derived from DLD1, have spontaneously acquired a G12D mutation in their single KRAS allele in 20% of the population. The present data suggest a relationship between KRAS mutations, particularly G13D, and the expression of the EPDR1 and ZNF518B genes and expression of their isoforms and provide enhanced understanding of the molecular mechanisms involved in the resistance of CRC cells to anti‑EGF receptor therapies.

View Figures

View References

1	Stewart BW and Wild CP: World Cancer Report 2014. IARC Publications; Lyon: 2014
2	Wong A and Ma BBY: Personalizing therapy for colorectal cancer. Clin Gastroenterol Hepatol. 12:139–144. 2014. View Article : Google Scholar : PubMed/NCBI
3	Van Cutsem E, Cervantes A, Nordlinger B and Arnold D: ESMO Guidelines Working Group: Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 25:(Suppl 3). iii1–iii9. 2014. View Article : Google Scholar : PubMed/NCBI
4	Brand TM, Iida M and Wheeler DL: Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 11:777–792. 2011. View Article : Google Scholar : PubMed/NCBI
5	Prior IA, Lewis PD and Mattos C: A comprehensive survey of Ras mutations in cancer. Cancer Res. 72:2457–2467. 2012. View Article : Google Scholar : PubMed/NCBI
6	Schubbert S, Shannon K and Bollag G: Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 7:295–308. 2007. View Article : Google Scholar : PubMed/NCBI
7	Dócs O, Fazakas F, Horváth NL, Tóth L, András C, Horváth Z and Méhes G: Changes of KRAS exon 2 codon 12/13 mutation status in recurrent colorectal cancer. Pathol Oncol Res. 21:399–404. 2015. View Article : Google Scholar : PubMed/NCBI
8	Roda D, Castillo J, Telechea-Fernández M, Gil A, López-Rodas G, Franco L, González-Rodríguez P, Roselló S, Pérez-Fidalgo JA, García-Trevijano ER, et al: EGF-induced acetylation of heterogeneous nuclear ribonucleoproteins is dependent on KRAS mutational status in colorectal cancer cells. PLoS One. 10:e01305432015. View Article : Google Scholar : PubMed/NCBI
9	Soh J, Okumura N, Lockwood WW, Yamamoto H, Shigematsu H, Zhang W, Chari R, Shames DS, Tang X, MacAulay C, et al: Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One. 4:e74642009. View Article : Google Scholar : PubMed/NCBI
10	Hartman DJ, Davison JM, Foxwell TJ, Nikiforova MN and Chiosea SI: Mutant allele-specific imbalance modulates prognostic impact of KRAS mutations in colorectal adenocarcinoma and is associated with worse overall survival. Int J Cancer. 131:1810–1817. 2012. View Article : Google Scholar : PubMed/NCBI
11	Malapelle U, Sgariglia R, De Stefano A, Bellevicine C, Vigliar E, de Biase D, Sepe R, Pallante P, Carlomagno C, Tallini G, et al: KRAS mutant allele-specific imbalance (MASI) assessment in routine samples of patients with metastatic colorectal cancer. J Clin Pathol. 68:265–269. 2015. View Article : Google Scholar : PubMed/NCBI
12	Costa V, Aprile M, Esposito R and Ciccodicola A: RNA-Seq and human complex diseases: Recent accomplishments and future perspectives. Eur J Hum Genet. 21:134–142. 2013. View Article : Google Scholar : PubMed/NCBI
13	Du J and Zhang L: Integrated analysis of DNA methylation and microRNA regulation of the lung adenocarcinoma transcriptome. Oncol Rep. 34:585–594. 2015.PubMed/NCBI
14	Panagopoulos I, Gorunova L, Zeller B, Tierens A and Heim S: Cryptic FUS-ERG fusion identified by RNA-sequencing in childhood acute myeloid leukemia. Oncol Rep. 30:2587–2592. 2013.PubMed/NCBI
15	Wang W, Qin Z, Feng Z, Wang X and Zhang X: Identifying differentially spliced genes from two groups of RNA-seq samples. Gene. 518:164–170. 2013. View Article : Google Scholar : PubMed/NCBI
16	Wang ET, Sandberg R, Luo S, Khrebtukova I, Zhang L, Mayr C, Kingsmore SF, Schroth GP and Burge CB: Alternative isoform regulation in human tissue transcriptomes. Nature. 456:470–476. 2008. View Article : Google Scholar : PubMed/NCBI
17	Matera AG and Wang Z: A day in the life of the spliceosome. Nat Rev Mol Cell Biol. 15:108–121. 2014. View Article : Google Scholar : PubMed/NCBI
18	Ladomery M: Aberrant alternative splicing is another hallmark of cancer. Int J Cell Biol. 2013:4637862013. View Article : Google Scholar : PubMed/NCBI
19	Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, Marth G, Abecasis G and Durbin R: 1000 Genome Project Data Processing Subgroup: The Sequence Alignment/Map format and SAMtools. Bioinformatics. 25:2078–2079. 2009. View Article : Google Scholar : PubMed/NCBI
20	Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ and Pachter L: Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol. 28:511–515. 2010. View Article : Google Scholar : PubMed/NCBI
21	Vitting-Seerup K, Porse BT, Sandelin A and Waage J: spliceR: An R package for classification of alternative splicing and prediction of coding potential from RNA-seq data. BMC Bioinformatics. 15:812014. View Article : Google Scholar : PubMed/NCBI
22	Simms D, Cizdziel P and Chomczynski P: TRIzol: A new reagent for optimal single-step isolation of RNA. Focus. 15:99–102. 1993.
23	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^ΔΔCT method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
24	Slattery ML, Pellatt DF, Mullany LE, Wolff RK and Herrick JS: Gene expression in colon cancer: A focus on tumor site and molecular phenotype. Genes Chromosomes Cancer. 54:527–541. 2015. View Article : Google Scholar : PubMed/NCBI
25	Shashoua VE: The role of brain extracellular proteins in neuroplasticity and learning. Cell Mol Neurobiol. 5:183–207. 1985. View Article : Google Scholar : PubMed/NCBI
26	Nimmrich I, Erdmann S, Melchers U, Chtarbova S, Finke U, Hentsch S, Hoffmann I, Oertel M, Hoffmann W and Müller O: The novel ependymin related gene UCC1 is highly expressed in colorectal tumor cells. Cancer Lett. 165:71–79. 2001. View Article : Google Scholar : PubMed/NCBI
27	Pradel G, Schachner M and Schmidt R: Inhibition of memory consolidation by antibodies against cell adhesion molecules after active avoidance conditioning in zebrafish. J Neurobiol. 39:197–206. 1999. View Article : Google Scholar : PubMed/NCBI
28	Hoffmann W and Schwarz H: Ependymins: Meningeal-derived extracellular matrix proteins at the blood-brain barrier. Int Rev Cytol. 165:121–158. 1996. View Article : Google Scholar : PubMed/NCBI
29	Shashoua VE, Adams D and Boyer-Boiteau A: CMX-8933, a peptide fragment of the glycoprotein ependymin, promotes activation of AP-1 transcription factor in mouse neuroblastoma and rat cortical cell cultures. Neurosci Lett. 312:103–107. 2001. View Article : Google Scholar : PubMed/NCBI
30	Jin TB, Ren Y, Shi X, Jiri M, He N, Feng T, Yuan D and Kang L: Genetic variations in the CLNK gene and ZNF518B gene are associated with gout in case-control sample sets. Rheumatol Int. 35:1141–1147. 2015. View Article : Google Scholar : PubMed/NCBI
31	Zhang XY, Geng TT, Liu LJ, Yuan DY, Feng T, Kang LL, Jin TB and Chen C: SLC2A9 and ZNF518B polymorphisms correlate with gout-related metabolic indices in Chinese Tibetan populations. Genet Mol Res. 14:9915–9921. 2015. View Article : Google Scholar : PubMed/NCBI
32	Maier VK, Feeney CM, Taylor JE, Creech AL, Qiao JW, Szanto A, Das PP, Chevrier N, Cifuentes-Rojas C, Orkin SH, et al: Functional proteomic analysis of repressive histone methyltransferase complexes PRC2 and G9A reveals ZNF518B as a G9A regulator. Mol Cell Proteomics. 14:1435–1446. 2015. View Article : Google Scholar : PubMed/NCBI
33	Shankar SR, Bahirvani AG, Rao VK, Bharathy N, Ow JR and Taneja R: G9a, a multipotent regulator of gene expression. Epigenetics. 8:16–22. 2013. View Article : Google Scholar : PubMed/NCBI
34	Zhao Z, Wang D, Zhu C, Shao H, Sun C, Qiu H, Xue L, Xu J, Guo M and Li W: Aberrant alternative splicing of human zinc finger gene ZNF268 in human hematological malignancy. Oncol Rep. 20:1243–1248. 2008.PubMed/NCBI